Compare ABUS & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABUS | GFR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.0M | 924.7M |
| IPO Year | 2008 | 2023 |
| Metric | ABUS | GFR |
|---|---|---|
| Price | $3.74 | $7.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.91 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | $1,208.75 | N/A |
| Revenue Next Year | N/A | $78.80 |
| P/E Ratio | $4.35 | ★ $4.33 |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.50 | $4.15 |
| 52 Week High | $5.45 | $7.16 |
| Indicator | ABUS | GFR |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 65.65 |
| Support Level | $3.50 | $5.59 |
| Resistance Level | $4.53 | N/A |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 15.82 | 97.29 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations. The company is actively developing its Hangingstone Facilities using SAGD, an enhanced oil recovery extraction method.